Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 764198 Efficacy and Safety in Prevention/Progression of ARDS and ARDS-related Complications Secondary to COVID-19 (ACTION ON COVID-19)

Next Previous
X
Search
Trial Profile

BI 764198 Efficacy and Safety in Prevention/Progression of ARDS and ARDS-related Complications Secondary to COVID-19 (ACTION ON COVID-19)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 764198 (Primary)
  • Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms ACTION ON COVID-19
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 06 Apr 2023 Interim Results(n=129) assessing efficacy and safety of the transient receptor potential channel C6 (TRPC6) inhibitor, BI 764198, in reducing the risk and/or severity of ARDS in patients hospitalised for COVID-19 published in the Thorax
    • 12 Mar 2021 According to a Boehringer Ingelheim media release, the decision is based on the recommendation of the trial independent Data Monitoring Committee after an interim look at unblinded safety and efficacy data showing a clear lack of benefit for use of BI-764198 in patients hospitalized for COVID-19 and needing oxygen support.
    • 12 Mar 2021 According to a Boehringer Ingelheim media release, the company decided to discontinue treatment in this study for reducing the risk or severity of acute respiratory distress syndrome (ARDS) in patients hospitalized for COVID-19 and requiring non-invasive oxygen support.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top